Trial Profile
Influence of the angiotensin receptor blocker telmisartan on the red blood cell function and the microcirculatory perfusion
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Telmisartan (Primary)
- Indications Hypertension
- Focus Pharmacodynamics
- Acronyms ITEM
- 28 Jan 2009 Actual end date (Jan 2009) added as reported by ClinicalTrials.gov.
- 28 Jan 2009 Status changed from not yet recruiting to discontinued as reported by ClinicalTrials.gov.
- 27 Nov 2007 New trial record.